Literature DB >> 15557791

Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary.

Hiroshi Tsuda1, Christina A Bandera, Michael J Birrer, Yasunori Hashiguchi, Ross S Berkowitz, Samuel C Mok.   

Abstract

OBJECTIVE: The purpose of this study is to compare DNA, mRNA and protein levels of the cyclin E between clear cell (CC) and serous (SC) ovarian carcinomas, and evaluate the relationship between cyclin E and p53 status.
METHOD: We examined the DNA, mRNA and protein levels of cyclin E and the protein level of p53 in 44 CCs and 39 SCs using microdissected tissues.
RESULTS: Relative cyclin E mRNA expression was significantly higher in CC (3.62, 95% CI, 2.24-4.99) than in SC (1.75, 95% CI, 1.05-2.45; p = 0.0098). The percentage of positive nuclear staining of cyclin E was significantly higher in CC (48.3, 95% CI, 40.4-56.1) than SC (25.3, 95% CI, 17.4-33.3; p = 0.0001). The mRNA and protein expression of cyclin E was significantly correlated (r = 0.66, p < 0.0001). However, the correlation between relative DNA copy number and relative mRNA expression was not significant (r = -0.063; p = 0.66). Percentage of positive nuclear staining of cyclin E was significantly higher in p53 positive cases (51.8, 95% CI, 40.0-63.5) than p53 negative cases (36.2, 95% CI, 28.2-44.2; p = 0.028).
CONCLUSIONS: Cyclin E expression is significantly higher in CC than in SC. Cyclin E expression is significantly related with p53 positivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557791     DOI: 10.1159/000081330

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.

Authors:  Hiroshi Kobayashi; Hitomi Sugimoto; Shunsuke Onishi; Kazutoshi Nakano
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

2.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

3.  Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease.

Authors:  Michael P Castro; Bradford P Whitcomb; Deborah A Zajchowski; Robert L Coleman
Journal:  Gynecol Oncol Res Pract       Date:  2015-08-28

4.  Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes.

Authors:  Giuseppina D'Andrilli; Antonio Giordano; Alessandro Bovicelli
Journal:  Open Clin Cancer J       Date:  2008-02-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.